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Background. The nephropathy induced by ureteral obstruc-
tion is associated with increased interstitial volume due to
matrix deposition, fibroblast differentiation/proliferation, and
monocyte infiltration. Recent studies indicate that trans-
forming growth factor- (TGF-) is linked to renal fibrosis.
Tumor necrosis factor (TNF-) has a role in the recruitment
of inflammatory cells. We found that infiltration of macro-
phages of the interstitium in unilateral ureteral obstruction
(UUO) occurred as early as four hours after the onset of UUO.
Methods. Recent studies indicate that a renal tubular devel-
opment morphogen, bone morphogenetic protein-7 (BMP-7),
is effective in preventing the tubulointerstitial nephritis in the
setting of obstructive nephropathy. The mechanism of action
appears to be preservation of epithelial cell phenotype, inhibi-
tion of epithelial-mesenchymal transdifferentiation, and inhibi-
tion of injury-induced epithelial cell apoptosis. Hepatocyte
growth factor (HGF) also inhibited tubulointerstitial fibrosis.
Results. In a treatment protocol in rats with ureteral ligation,
BMP-7 restored renal function. The preservation of glomerular
filtration rate (GFR) was accompanied by a significant decrease
in cortical interstitial volume. In diabetic rats given BMP-7
proteinuria was normalized. In mice with ureteral obstruction,
HGF suppressed the expression of TGF- and of platelet-
derived growth factor. The onset of tubulointerstitial fibrosis
was almost completely inhibited by HGF.
Conclusion. Both BMP-7 and HGF attenuate the tubuloin-
terstitial fibrosis due to ureteral obstruction. They also increase
GFR and renal plasma flow.
Progression of renal disease to end-stage renal disease
(ESRD) is a major problem throughout the world. The
result of slow, but persistent, decline of renal function
is the major cause of ESRD. This process is accompanied
by progressive tubulointerstitial injury and renal fibrosis.
Inflammation of the tubulointerstitial compartment,
leading to fibrosis, is a major factor in the progressive
loss of renal function in patients with a wide variety
of kidney diseases. About 80% of the total kidney is
composed of tubule epithelial cells and cells within the
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interstitial space. Most of the nonepithelial cells are asso-
ciated with the rich vascular network of the kidney.
There are also a small number of resident mononuclear
cells and fibroblasts. A model of renal fibrosis that en-
compasses many aspects of other models of kidney dis-
ease is unilateral ureteral obstruction (UUO).
Nephropathies induced by the administration of strep-
tozotocin, cyclosporin, aminonucleoside, adriamycin, an-
giotensin II (Ang II), and by UUO are associated with
increased interstitial volume due to matrix protein depo-
sition, fibroblast differentiation/proliferation, and mono-
cyte infiltration [1–3]. In an attempt to maintain the
integrity of the tubules, there is an activation of prolifera-
tive pathways within the epithelial cells. If the prolifera-
tive forces or homeostatic factors within the kidney dissi-
pate, the apoptotic pathway(s) overwhelm the ability
of tubule epithelial cells to survive and tubule atrophy
develops.
A marked vasoconstriction of the kidney vascular bed
is the predominant alteration observed after 24 hours of
ureteral obstruction. Both the glomerular filtration rate
(GFR) and effective renal plasma flow (ERPF) de-
creased, and mean arterial pressure increased after uni-
lateral release of bilateral ureteral obstruction (BUO).
Considered together, investigations thus far suggest
that an imbalance between vasoconstrictor and vasodila-
tor substances may explain the hemodynamic alterations
(decreased GFR, decreased ERPF) seen in obstructive
nephropathy.
TRANSFORMING GROWTH FACTOR-
In the last decade, many of the cellular and molecular
changes of obstructive nephropathy have been attributed
to an increase in the expression of transforming growth
factor- (TGF-). Two recent studies indicate that the
increased expression of TGF- is indeed linked to renal
fibrosis [4, 5]. In a rat model of UUO, retrograde infusion
of HVS liposome–encased antisense oligonucleotide spe-
cific for TGF-1 attenuated the increase in interstitial
volume [4]. There was a decrease in macrophage infiltra-
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Table 1. Factors that are increased in the setting
of ureteral obstruction
Vasoactive compounds
Angiotensinogen
Angiotensin II
Endothelin
Thromboxane A2
Prostaglandins
Transforming growth factor-
Protein 53
Protein 21 (WAF1)
Tissue inhibitor of metalloproteinase-1
Decorin
Nuclear factor  B
Tumor necrosis factor-
Proto-oncogenes
c-fos
c-jun
jun B
c-myc
cH-Ras
Growth factors
Interleukin-6
Platelet-activating factor
Basic fibroblast growth factor
Proteins involved in apoptosis
Clusterin (SGP-2)
Osteopontin
Chemoattractants
Monocyte chemoattractant peptide-1
Osteopontin
Adhesion proteins
Intercellular adhesion molecule-1
Vascular cell adhesion molecule-1
Fibronectin (alternate splice forms)
Matrix/basement membrane proteins
Collagen types I, III, IV, XV, and XVIII
tion, myofibroblast formation, and collagen I deposition.
In another study, Miyajima et al [5] treated rats with
UUO with a neutralizing antibody to TGF-. This re-
sulted in less tubular atrophy. The induction of p53 was
blunted, whereas Bcl-2 and inducible nitric oxide syn-
thase (iNOS) expression were increased. This is inconsis-
tent with the authors’ hypothesis that iNOS serves a
protective role in obstructive nephropathy. These studies
indicate that TGF- alters the fibrotic forces within the
kidney. All investigations in animal models suggest that
TGF- is increased in kidneys with UUO. Kaneto et al
[6] show that this is true in the kidneys of patients with
UUO. Material from kidneys of nine patients with carci-
noma of the ureter was compared with the normal por-
tion of kidneys of eight patients with renal cell carci-
noma. The patients were age and gender matched. There
was a significant increase in TGF-1 mRNA in the pa-
tients with an obstructed ureter. The amount of collagen
IV and fibronectin mRNA was also found to be increased
[6]. This study suggests that animal models of UUO
are reflective of the molecular changes seen in human
obstructive nephropathy (see Tables 1 and 2).
Table 2. Factors that are decreased in the setting
of ureteral obstruction
Growth or homeostatic factors
Bone morphogenetic protein-7 (BMP-7)
Hepatocyte growth factor
Epidermal growth factor
Redox state
Copper, zinc superoxide dismutase
Catalase
Reduced glutathione
Others
Inducible nitric oxide synthase
TUMOR NECROSIS FACTOR-
Tumor necrosis factor (TNF-) has a role in the re-
cruitment of inflammatory cells in animal models of glo-
merular injury. It stimulates the production of one or
more chemotactic factors by resident cells and specifi-
cally up-regulates macrophage chemoattractant protein-1
(MCP-1) mRNA in human mesangial cells.
We found that macrophages infiltrated the interstitium
of the obstructed kidney cortex as early as four hours
after the onset of UUO, and by 24 hours the influx
was 10-fold greater than normal. These observations
suggest that an early increase in TNF- after UUO of
the kidney up-regulates the production of a chemoattrac-
tant(s) for monocytes and contributes to the infiltration
of the obstructed kidney by leukocytes.
In another study, we examined the contribution of
TNF- to the pathophysiology of the interstitial fibrosis
that occurs after UUO, using mice in which the known
receptors to TNF- had been deleted through genetic
means [7, 8]. This allowed us to determine whether
TNF- is a contributory factor to the pathophysiology
of obstructive nephropathy.
The vast majority of studies concerning tubulointersti-
tial fibrosis have utilized the rat model. The power of
genetics and the ability to manipulate the genetics of the
mouse have been used in our studies. Mice in which
TNF- receptors TNFR1 and TNFR2 had been geneti-
cally knocked out were used and the results were com-
pared with those from mice of C57BL/6 background after
5 days of UUO [7]. The changes in interstitial volume
of the contralateral unobstructed kidneys averaged 7%
and were indistinguishable among the three genotypes
of mice.
Interstitial volume of the UUO kidney of C57BL/6
mice averaged 33%  3.9% after 5 days of UUO. Inter-
stitial volume of the obstructed kidneys of TNFR1 mice
was significantly reduced to 19.4% 3.1%, whereas that
of TNFR2 mice was significantly decreased to 25.4% 
4.8%. There was a modest but significant difference be-
tween interstitial volume of TNFR1 and TNFR2 mice
(P 0.047). Both collagen IV and -smooth muscle actin
matrix scores were decreased significantly in the ob-
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structed kidneys of TNFR1 mice compared with those of
C57BL/6 and TNFR2 mice. Nuclear extracts prepared
from kidney cortex had a significant increase in nuclear
factor kappa B (NF-B) binding activity in the obstructed
kidneys compared with the contralateral kidneys. Indi-
vidual knockout of the TNFR1 or TNFR2 genes resulted
in significantly less NF-B activation compared with
wild-type, with TNFR1 knockout values being less than
those in TNFR2 knockout mice [7]. There was a signifi-
cant increase in TNF-mRNA in the kidneys with UUO
in all three genotypes. TNFR1 knockout mice displayed
a significant reduction in the amount of TNF- mRNA
induced compared with wild-type or TNFR2 knockout
mice. Treatment of TNFR1 knockout [7] or TNFR1 and
TNFR2 double knockout [8] mice with an orally active
angiotensin-converting enzyme (ACE) inhibitor enala-
pril further decreased interstitial volume and TNF-
mRNA induction, suggesting an interaction of the Ang II
and TNF- systems. These results suggest that TNF-
contributes, in part, to interstitial volume, myofibroblast
differentiation, and NF-B activation in the kidney dur-
ing UUO. These changes appear to be mediated through
both TNFR1 and TNFR2 gene products, with effects
through the TNFR1 receptor predominating. Further-
more, Ang II appears to stimulate TNF-–related patho-
physiologic events leading to renal fibrosis, and together
they can account for 70% to 80% of the pathophysio-
logic changes in obstructive nephropathy [8].
ENDOTHELIN SYSTEM
Recent studies indicate that endothelin, a powerful
vasoconstrictive peptide, may play an important role in
some types of renal disease. To investigate the effects
of Ang II on endothelin and its receptors in the kidney,
mice were subjected to UUO and treated with or without
enalapril in their drinking water (100 mg/L) [9]. The
animals were killed five days later. Using reverse tran-
scription (RT) coupled with polymerase chain reaction
(PCR), we measured the levels of endothelin-1 (ET-1),
endothelin A, (ETA), and endothelin B (ETB) along with
TGF-, TNF-, and collagen type IV mRNA expression
in the kidney with UUO, and the contralateral kidney
along with interstitial expansion in the kidney cortex
by a standard point-counting method. We found that
enalapril administration ameliorated the increased ex-
pression of ET-1 mRNA in the obstructed kidney by
44% (P  0.02). Although the level of ETA mRNA
expression was significantly increased in the obstructed
kidney, it was not affected by enalapril. We found that
enalapril treatment increased ETB mRNA expression by
115% (P  0.05) and protein expression (measured by
Western blot) in the kidney with an obstructed ureter.
Enalapril treatment alone inhibited the expansion of in-
terstitial volume due to UUO by 52%. Cotreatment with
enalapril and the ETB receptor antagonist BQ-788 inhib-
ited the expression of interstitial volume by only 19%.
This study confirms that enalapril inhibits the interstitial
fibrosis in UUO kidneys. It also suggests a beneficial and
unforeseen effect of enalapril on the obstructed kidney
by potentially stimulating the production of nitric oxide
(NO) through an increased expression of the ETB re-
ceptor.
APOPTOSIS IN OBSTRUCTIVE NEPHROPATHY
Prolonged ureteral ligation induces marked hydro-
nephrosis of the affected kidney and is accompanied by
tissue loss (evident by a marked reduction in kidney
weight), atrophy of tubular epithelial cells, and the devel-
opment of interstitial inflammation and fibrosis. Truong
et al [10] have examined the effects of obstructive uropa-
thy on cell proliferation and apoptosis. Rats with UUO
were killed at several intervals between 1 and 90 days
after the induction of obstruction and were compared
with control sham-operated rats. Obstructed kidneys,
contralateral kidneys, and kidneys from normal rats were
subjected to in situ end-labeling of fragmented DNAs
to detect apoptotic cells, and were immunostained with
monoclonal antibodies directed against the nuclear anti-
gens associated with cell proliferation. Apoptosis of tu-
bular cells from kidneys with chronic obstructive ne-
phropathy increased rapidly, reaching 30-fold that of
control by 25 days of obstruction [10]. This peak was
followed by a rapid decrease to control levels. In the 25
days after the onset of obstruction, both kidney dry
weight and mean tubular diameter decreased signifi-
cantly. Thus, apoptosis contributes to the tubular atrophy
and renal weight loss observed in prolonged obstructive
nephropathy. The rapid increase in tubular cell apoptosis
was preceded by a 37% gain in kidney dry weight com-
pared with control. No apoptosis or proliferation of glo-
merular cells was observed during the course of this
study. These observations suggest that tubular cell apo-
ptosis might be pathogenetically related to the tubular
atrophy and renal tissue loss that occur in animals or
humans [1] with chronic obstructive nephropathy.
A large number of factors can initiate apoptosis, sev-
eral of which may be pertinent to obstructive nephropa-
thy, such as hypoxia, ischemia, cytokines, growth factors,
Ang II, TNF-, reactive oxygen species, and mechanical
stretch. These factors act on a family of cell membrane
receptors that include the TNF receptor and Fas (also
known as CD95 or APO-7). Members of this family share
a common intracytoplasmic domain called the death do-
main [11].
The increase in apoptosis is associated with an increase
in p53 mRNA [12, 13]. This finding suggests that p53
activation may have a role in the development of apopto-
sis after UUO [13]. In a recent study [12], genetically
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engineered mice were used to examine the role of p53
in renal cell apoptosis in obstructive nephropathy. Ob-
structed kidneys in p53/, p53/, and p53/ mice
were examined for apoptosis, members of the bcl-2 fam-
ily, the death receptor family, and the common effectors
of apoptosis. Obstructed kidneys in p53/ and p53/
mice exhibited equal attenuation of tubular and intersti-
tial cell apoptosis (70% and 50%, respectively) com-
pared with p53/ mice. However, p53 gene deficiency
did not confer complete protection from apoptosis.
These data suggest that apoptosis in obstructed kidneys
involves p53-dependent as well as p53-independent path-
ways. The p53-dependent pathway may involve activa-
tion of caspases-1, -11, and -12, whereas the p53-indepen-
dent pathway may involve activation of members of the
bcl-2 and death receptor families. Caspases are a family
of cytoplasmic enzymes that are normally present in the
cytoplasm in inactive forms. Activated caspases repre-
sent the central effector molecules of apoptosis [12, 13].
ROLE OF BONE MORPHOGENETIC PROTEIN-7
IN RENAL DISEASE
Recent studies indicate that a renal tubular devel-
opmental morphogen, bone morphogenetic protein-7
(BMP-7), is effective in preventing the tubulointerstitial
nephritis in the setting of obstructive nephropathy
[14, 15]. The mechanism of action appears to be preserva-
tion of epithelial cell phenotype, inhibition of epithelial-
mesenchymal transdifferentiation, and inhibition of in-
jury-induced epithelial cell apoptosis.
INTERSTITIAL VOLUME
UUO is characterized by a progressive increase of
the interstitial volume of the kidney cortex. Even after
release of the ligation, profibrotic forces still prevail,
such that the interstitial volume increases from the 7%
to 8% found in the kidneys of sham-operated animals
to the 17% to 20% found in the obstructed-released
kidneys. If the obstruction had not been released, the
interstitial volume would have increased to approxi-
mately 50% by 10 days of continuous obstruction [14–16].
In the control, vehicle-treated animals, the interstitial
volume averaged 19.8 1.1. This was slightly but signifi-
cantly decreased by enalapril treatment to 18.1% 1.2%
(P 0.05). Treatment with BMP-7 in these rats was more
effective, decreasing the interstitial volume to 17.1% 
0.08% (P  0.01). Combining enalapril and BMP-7 did
not produce any additive or synergistic effects. Although
the changes in the interstitial volumes were small, it
must be kept in mind that BMP-7 treatment blunted the
increase above a baseline of 7% by 21%.
Table 3. Tubule diametera
Rat Diameter, meanSD (m)
Sham operated 714
Vehicle treated 536b
Enalapril treated 595c
BMP-7 treated 654d
Enalapril and BMP-7 treated 595c
BMP-7 is bone morphogenetic protein-7.
aThe tubule diameter of the contralateral unobstructed kidneys was not sig-
nificantly different from the value of the kidney of sham-operated animals.
bP  0.0005 vs. sham
cP  0.01 vs. sham
dP  0.05 vs. sham; P  0.002 vs. vehicle; P  0.04 vs. enalapril or enalapril
and BMP-7
COLLAGEN IV MATRIX
In the kidney of normal or sham-operated animals
and the contralateral kidneys of rats with UUO, collagen
IV is found in the basement membrane surrounding tu-
bules, in capillaries, and in the mesangial matrix. In the
setting of fibrosis associated with UUO, collagen IV be-
comes an interstitial matrix protein [14–16] in addition
to its presence in basement membranes. The collagen IV
matrix score is another means of quantifying interstitial
fibrosis.
Animals treated with enalapril had a modest but sig-
nificant (P  0.05) decrease in the collagen IV matrix
score by 15% compared with vehicle. Administration of
BMP-7 significantly decreased the matrix score (P 
0.005) by approximately 27% when the baseline score
of 0.15 is subtracted from each value. A combination
of BMP-7 and enalapril also significantly (P  0.02)
decreased the collagen IV matrix score by 20%, but this
was not different from either treatment alone.
TUBULE DIAMETER
There is an inexorable loss of tubule epithelial cells
through apoptosis during the progression of kidney dis-
ease [17, 18], resulting in tubule atrophy. This loss can
be measured at intervals of time by the terminal deoxy-
nucleotidyl transferase-mediated dUTP nick-end label-
ing (TUNEL) assays as the number of cells undergoing
apoptosis at that point in time. Another means by which
tubule atrophy may be determined is by measuring tu-
bule diameter, which would be an index of all apoptotic
cell loss up to that point in time when the kidney biopsy
is obtained (see Table 3).
RENAL FUNCTION STUDIES:
PREVENTION PROTOCOL
The presumption of these studies is that detrimental
changes in the histologic appearance of the kidney are
reflected in concomitant decreases in renal function.
Conversely, ameliorative changes in histologic appear-
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ance should translate into better renal function. GFR
was decreased by about half, whereas renal blood flow
(RBF) was decreased by approximately 20% in the ob-
structed-released kidney of vehicle-treated rats com-
pared with sham-operated rats. The reduction in GFR
was significant (P  0.02). Treatment with enalapril
alone (P 0.07) tended toward, but was not significantly
different from, vehicle treatment. Animals that had been
treated with BMP-7 had a significant recovery of GFR
compared with vehicle treatment (P  0.01) and were
statistically indistinguishable (P	 0.10) from sham-oper-
ated rats. Treatment with a combination of enalapril and
BMP-7 was on average as effective, but because of the
wider SD, it was not statistically different from treatment
with vehicle (P  0.12). In these experiments, RBF was
not significantly different between the groups of animals.
All animals had renal function after release of the ob-
struction as measured at day 10 or 7 days after relief of
the obstruction of 3 days’ duration.
RENAL FUNCTION STUDIES:
TREATMENT PROTOCOL
The prevention protocol clearly suggests that BMP-7
given at the initiation of and throughout the 10-day pe-
riod of experimental renal disease preserves renal func-
tion. In the treatment protocol, the BMP-7 was withheld
until the time that the obstruction was surgically cor-
rected. After seven days of release with concomitant
treatment, it was found that BMP-7 significantly restored
or accelerated the return of renal function. This treat-
ment protocol included three new sham-operated and
five new vehicle-treated rats, along with the four BMP-
7–treated animals. There was a significant restoration
(P  0.001) of renal function, measured as GFR in the
BMP-7 treatment group compared with vehicle treat-
ment. Treatment with BMP-7 increased GFR more than
four-fold above vehicle treatment, such that 70% of GFR
was restored [16].
This significant preservation of GFR was accompanied
by a significant decrease in the interstitial volume (P 
0.001) in the BMP-7 treatment group compared to vehi-
cle. In this group of animals, the cortical interstitial vol-
ume of the obstructed-released kidney was 25.0% 
2.3%. This was reduced to 15.4%  2.1% by BMP-7
treatment, which was modestly but significantly elevated
(P  0.025) above the cortical interstitial volume of the
kidney in sham-operated rats.
THE ROLE OF BMP-7 IN
DIABETIC NEPHROPATHY
Recently, we have examined the effects of administra-
tion of BMP-7 in rats with diabetes induced by a single
dose of streptozotocin. After 16 weeks, glomerular hy-
pertrophy and proteinuria were established, and therapy
with BMP-7 (10, 30, or 100 g/kg intravenously twice a
week), enalapril (20 mg/kg), or vehicle was began and
continued for 32 weeks. Kidney weight, GFR, urine pro-
tein excretion, blood pressure, pathology, and BMP-7
expression were measured by Wang et al [19].
Diabetic rats given vehicle developed renal insuffi-
ciency by 32 weeks (GFR 0.34 0.02 mL/min/100 g body
weight, P  0.01 vs. 0.55  0.02 mL/min/100 g body
weight in normal). Diabetic rats given BMP-7 (high dose)
had a GFR of 0.70  0.08 mL/min/100 g body weight,
which was higher than diabetic rats treated with enalapril
(0.58 0.06), both at 32 weeks. This should be compared
to the GFR of 1.42  0.24 mL/min/100 g body weight
at week 16 due to hyperfiltration and hypertrophy. Pro-
teinuria was normalized by BMP-7 in a dose-dependent
manner. Glomerular area and interstitial volume were
significantly decreased in rats given BMP-7 or enalapril.
Glomerular sclerosis was prevented by BMP-7 therapy
more effectively than by enalapril. Enalapril controlled
hypertension throughout the course of therapy, while
BMP-7 did not affect blood pressure until the final 4
weeks of therapy. Interestingly, both enalapril treatment
and exogenous BMP-7 treatment significantly preserved/
restored endogenous BMP-7 synthesis within the kidney.
HEPATOCYTE GROWTH FACTOR
This growth factor (HGF) was first identified in 1984
and purified as a potent mitogen of primary cultured
hepatocytes [20]. Molecular cloning revealed that it is a
heterodimeric molecule composed of a 69 kD -chain
and a 34 kD -chain. The -chain contains an N-terminal
domain and subsequent four-kringle domains, with the
-chain containing a serine protease-like domain with
no enzymatic activity [21].
HGF is synthesized and secreted as a biologically inac-
tive single-chain precursor form, and further processing
by serine proteases into the two-chain form is coupled
to its activation. Serine proteases responsible for the
activation of HGF include HGF activator or HGF-con-
verting enzyme and urokinase-type plasminogen activa-
tor (uPA) [22]. The receptor for HGF was identified as
a c-Met proto-oncogene product [23]. The c-Met recep-
tor is composed of a 50 kD -chain and 145 kD -chain.
The -chain is exposed extracellularly, while the -chain
is a transmembrane subunit containing an intracellular
tyrosine kinase domain. Binding of HGF to the c-Met
receptor induces activation of tyrosine kinase, an event
that results in subsequent phosphorylation of C-termi-
nally clustered tyrosine residues [23].
The essential role for HGF and the c-Met receptor in
mammalian development was defined by the disruption
of HGF or the c-Met gene in mice; these mice died during
development (embryonic days 13 to15) as organogenesis
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of the placenta and liver was impaired. HGF is also
involved in the formation of the kidney, lung, mammary
gland, teeth, muscle, and neuronal tissues.
Increased levels of HGF were observed in patients
with acute renal failure, in contrast to detectable but low
levels of HGF in the urine of healthy subjects and in
patients with chronic glomerular or polycystic disease
[24, 25]. Serum HGF levels are elevated in patients with
chronic renal failure [26]. Immunohistochemical analysis
revealed positive staining for HGF to be 33.3% for IgA
nephropathy, 66.7% for membranous glomerulonephri-
tis, and 50% for focal glomerulosclerosis. All patients
with drug-induced interstitial nephritis were positive for
HGF staining, but no such staining was observed in pa-
tients with minimal change. In patients with renal cystic
diseases, the HGF level in the proximal cyst fluid is high
(mean 2.45 ng/mL) compared with that in the distal cyst
fluid (0.42 ng/mL). Immunohistochemical staining showed
a significant positive correlation between the distribution
of HGF and histologic damage, the grade of tubulointer-
stitial lesion, and several clinical parameters determined
at biopsy in patients with IgA nephropathy (P  0.01).
In human kidneys that are rejected, transcription of HGF
mRNA in the urinal tubular epithelium and in the mes-
enchymal cells (fibroblasts and smooth muscle cells in
chronic vascular rejection and endothelial cells and/or
mesangial cells in transplant glomerulopathy) has been
observed.
The potential therapeutic roles of HGF in renal dis-
eases are summarized in recent reviews [27–32]. Intrave-
nous injection of recombinant human (rh)-HGF given
to mice suppressed increases in blood urea nitrogen and
serum creatinine caused by the administration of cis-
platin, or by HgCl2. This indicates that HGF prevents
the onset of acute renal dysfunction. Also, exogenous
HGF stimulated DNA synthesis of renal tubular cells
after renal injury by HgCl2 administration and unilateral
nephrectomy. Cyclosporin A (CsA) is a potent, widely
prescribed immunosuppressant that has serious side ef-
fects. When rh-HGF was co-administered with CsA to
mice, severe digestive and/or neurologic symptoms and
degenerative changes in renal tubular cells and tubulo-
interstitial fibrosis hepatocytes seen with cases of CsA
administration were markedly attenuated. Also, mortality
linked to CsA administration was prevented by rh-HGF
treatment [33]. Using mice with UUO, the role of HGF
was investigated in tubulointerstitial fibrosis. Neutraliza-
tion of endogenous HGF accelerated the progression of
tubulointerstitial fibrosis, accompanied by increases in
TGF- expression and tubular apoptosis, as well as by
decreases in tubular proliferation. In contrast, rh-HGF
attenuated tubulointerstitial fibrosis progression, and
there were decreases in TGF- expression and tubular
apoptosis, and an increase in tubular proliferation [31].
There was a preventive effect of HGF on the progression
fibrosis, in a spontaneous mouse model (ICGN strain)
of chronic renal disease, which is generally thought to
be incurable except by renal transplantation. The mice
progressively developed glomerular sclerotic injury, tu-
bular atrophy, and renal dysfunction until they were 17
weeks of age. Recombinant human HGF was given to
these mice during a four-week period (from weeks 14
to 17 after birth), DNA synthesis of tubular epithelial
cells was found to be 4.4-fold higher than in mice without
HGF injection, thereby suggesting that tubular paren-
chymal expansion is promoted by HGF. Notably, HGF
suppressed the expression of TGF- and of platelet-
derived growth factor, as well as myofibroblast formation
in the affected kidney. Consequently, the onset of tubu-
lointerstitial fibrosis was almost completely inhibited by
HGF, while HGF attenuated the progression of glomeru-
losclerosis, both leading to a prevention of the manifesta-
tion of renal dysfunction [30]. In addition, in chronic
renal failure/fibrosis in ICGN mice, HGF in the kidney
declines in a manner reciprocal to the increase in TGF-.
Antibody neutralization of HGF leads to acceleration
of renal failure/fibrosis, while HGF administration leads
to remarkable attenuation [31].
HGF gene therapy is a feasible option for treating
ischemic damage of the kidney, or acute and chronic
renal failure, as follows. A single injection of the HGF
gene using the hemagglutinating virus of Japan (HVJ)
liposomes gave a low but continuous intravenous level
of HGF and attenuated ischemic damage in the kidney
[34]. Intravenous systemic administration of a naked
plasmid containing human HGF cDNA produced sub-
stantial levels of human HGF protein in mouse kidneys,
and significantly ameliorated renal dysfunction and ac-
celerated recovery from the acute injury induced by folic
acid. HGF gene delivery using a naked plasmid vector,
in a similar manner, markedly ameliorated renal fibrosis
in an animal model of chronic renal disease induced
by UUO [32]. These findings suggest the possibility of
treating subjects with renal diseases using an rh-HGF
protein and an HGF gene.
ARGININE AND NITRIC OXIDE
We also have examined the potential role of another
vasodilator, NO, in the changes in GFR and ERPF ob-
served after unilateral release of BUO. We found that
administering arginine, the precursor of NO, prior to ob-
struction markedly increased GFR and effective plasma
flow after release of obstruction in the experimental kid-
ney [35]. On the other hand, the administration of a
competitive inhibitor of arginine prior to release of ob-
struction resulted in total obliteration of renal function
in the post-obstructed kidney of the rat. These studies
suggest an important role for NO or endothelial-derived
relaxing factor in the hemodynamic events that occur
Klahr and Morrissey: Obstructive nephropathy and renal fibrosis S-111
following obstruction of the urinary tract. In other stud-
ies, rats with BUO given a specific anti-endothelin anti-
body were found to have significantly higher GFR and
ERPF than BUO control rats, indicating that endothelin
has an important role as a vasoconstrictor in rats with
BUO.
RENAL DISEASE: ROLE OF L-ARGININE
AND NITRIC OXIDE
In the rat model of subtotal renal ablation, less NO
is formed in the kidney, apparently due to a progressive
decrease in the amount of iNOS. In this setting, a reduc-
tion in NO synthesis, together with the local generation
of vasoconstrictors and cytokines, may contribute to pro-
gressive renal insufficiency. In rats with subtotal ablation,
administration of l-arginine for six weeks reduced the
degree of glomerulosclerosis. It was suggested that this
animal model is characterized by low renal NO produc-
tion and that long-term administration of l-arginine was
beneficial by adding substrate for the generation of NO.
In this model of subtotal renal ablation, a progressive
decrease in iNOS immunostaining was observed. In con-
trast, endothelial NOS (eNOS) staining was no different
in kidneys of rats with subtotal renal ablation from that
of normal kidneys in control rats. Administration of do-
nors of NO to rats with subtotal renal ablation reduced
proteinuria, slowed the progression of renal disease, and
prolonged the survival of these animals [36]. By contrast,
increased amounts of NO appear to be released into the
systemic circulation of rats with subtotal renal ablation.
This regulation may ameliorate, to some extent, the de-
gree of hypertension that occurs in this model [37]. The
progressive decrease in iNOS seen in the 5/6 nephrec-
tomy model and worsening of fibrosis are reminiscent
of the decrease in iNOS during UUO [5]. This protective
role of iNOS in obstructive nephropathy is consistent
with inhibition of NOS blunting the ameliorative effect
of ACE inhibition [38]. Furthermore, activation of the
ETB receptor can contribute to nitric oxide production
and blunt the progression of fibrosis [9].
CONCLUSION
The beneficial effect of HGF treatment can be related
directly to decreases in TGF-1, myofibroblast forma-
tion, and apoptosis. Measurements of renal function dur-
ing HGF treatment have not been rigorously performed.
The beneficial effect of BMP-7 treatment has been re-
lated to reduction in apoptosis, myofibroblast formation,
and tubule atrophy. In this case, however, renal function
has been restored in two models of renal disease. Re-
cently, it has been shown that BMP-7 antagonizes TGF-
dependent fibrogenesis in mesangial cells [39]. Whether
BMP-7 decreases TNF- or ET-1 remains to be deter-
mined. Whether HGF or BMP-7 affects NO levels also
remains to be shown.
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